5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer
Open Access
- 1 August 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 174 (8) , 1301-1307
Abstract
Prostate cancer is the second leading cause of cancer mortality in US men and the most commonly diagnosed noncutaneous malignancy.1 North American men have a 1 in 6 lifetime risk of prostate cancer diagnosis with a median age at diagnosis of 67 years.1 Owing to the high incidence of prostate cancer and the significant personal and public costs associated with diagnosis and treatment, preventive measures would have a powerful impact on reducing associated morbidity and mortality. In addition, prostate cancer is well suited for chemoprevention efforts because of its long latency period and multistep pathogenesis.2Keywords
This publication has 34 references indexed in Scilit:
- Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsCancer, 2012
- Prostate-Cancer Mortality at 11 Years of Follow-upNew England Journal of Medicine, 2012
- Smoking and Prostate Cancer Survival and RecurrenceJAMA, 2011
- A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer TreatmentCancer Discovery, 2011
- Coffee Consumption and Prostate Cancer Risk and Progression in the Health Professionals Follow-up StudyJNCI: Journal of the National Cancer Institute, 2011
- Reduced levels of 5‐α reductase 2 in adult prostate tissue and implications for BPH therapyThe Prostate, 2011
- Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening TrialBritish Journal of Cancer, 2009
- Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineJournal of Clinical Oncology, 2009
- Prostate cancer: a serious disease suitable for preventionBJU International, 2009
- Diabetes mellitus and risk of prostate cancer in the health professionals follow‐up studyInternational Journal of Cancer, 2008